Cerity Partners LLC Sells 612 Shares of Illumina, Inc. (NASDAQ:ILMN)

Cerity Partners LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,957 shares of the life sciences company’s stock after selling 612 shares during the period. Cerity Partners LLC’s holdings in Illumina were worth $691,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Illumina during the third quarter valued at approximately $30,000. VisionPoint Advisory Group LLC boosted its holdings in Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the period. Riverview Trust Co grew its position in Illumina by 203.5% in the 3rd quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock valued at $36,000 after acquiring an additional 175 shares during the last quarter. Gradient Investments LLC increased its stake in Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 225 shares during the period. Finally, North Star Investment Management Corp. lifted its position in shares of Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after purchasing an additional 194 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In related news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Stock Up 3.5 %

Shares of Illumina stock opened at $124.46 on Wednesday. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $229.58. The firm’s 50 day moving average price is $132.79 and its 200-day moving average price is $127.58. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The company has a market cap of $19.82 billion, a P/E ratio of -16.96 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 earnings per share. On average, sell-side analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of research analyst reports. TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a report on Thursday, January 4th. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.